Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.

Abstract : Chemoresistance of glioblastoma multiforme (GBM) has been attributed to the presence within the tumor of cancer stem cells (GSCs). The standard therapy for GBM consists of surgery followed by radiotherapy and the chemotherapeutic agent temozolomide (TMZ). However, TMZ efficacy is limited by O6-methylguanine-DNA-methyltransferase (MGMT) and Mismatch Repair (MMR) functions. Strategies to counteract TMZ resistance include its combination with poly(ADP-ribose) polymerase inhibitors (PARPi), which hamper the repair of N-methylpurines. PARPi are also investigated as monotherapy for tumors with deficiency of homologous recombination (HR). We have investigated whether PARPi may restore GSC sensitivity to TMZ or may be effective as monotherapy. Ten human GSC lines were assayed for MMR proteins, MGMT and PARP-1 expression/activity, MGMT promoter methylation and sensitivity to TMZ or PARPi, alone and in combination. Since PTEN defects are frequently detected in GBM and may cause HR dysfunction, PTEN expression was also analyzed. The statistical analysis of the differences in drug sensitivity among the cell lines was performed using the ANOVA and Bonferroni's post-test or the non-parametric Kruskal-Wallis analysis and Dunn's post-test for multiple comparisons. Synergism between TMZ and PARPi was analyzed by the median-effect method of Chou and Talalay. Correlation analyses were done using the Spearman's rank test. All GSCs were MMR-proficient and resistance to TMZ was mainly associated with high MGMT activity or low proliferation rate. MGMT promoter hypermethylation of GSCs correlated both with low MGMT activity/expression (Spearman's test, P = 0.004 and P = 0.01) and with longer overall survival of GBM patients (P = 0.02). Sensitivity of each GSC line to PARPi as single agent did not correlate with PARP-1 or PTEN expression. Notably, PARPi and TMZ combination exerted synergistic antitumor effects in eight out of ten GSC lines and the TMZ dose reduction achieved significantly correlated with the sensitivity of each cell line to PARPi as single agent (P = 0.01). The combination of TMZ with PARPi may represent a valuable strategy to reverse GSC chemoresistance.
Type de document :
Article dans une revue
BMC Cancer, BioMed Central, 2014, 14, pp.151. 〈10.1007/s00280-013-2175-0〉
Liste complète des métadonnées

https://hal-riip.archives-ouvertes.fr/pasteur-01164062
Contributeur : Istituto Pasteur Fondazione Cenci Bolognetti <>
Soumis le : mardi 16 juin 2015 - 10:07:22
Dernière modification le : lundi 8 octobre 2018 - 17:44:06
Document(s) archivé(s) le : mardi 25 avril 2017 - 08:30:34

Fichier

1471-2407-14-151.pdf
Publication financée par une institution

Licence


Distributed under a Creative Commons Paternité 4.0 International License

Identifiants

Collections

Citation

Lucio Tentori, Lucia Ricci-Vitiani, Alessia Muzi, Fabio Ciccarone, Federica Pelacchi, et al.. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.. BMC Cancer, BioMed Central, 2014, 14, pp.151. 〈10.1007/s00280-013-2175-0〉. 〈pasteur-01164062〉

Partager

Métriques

Consultations de la notice

76

Téléchargements de fichiers

84